Request Trial
omersukrugoksu-istockphoto-com-italy-
omersukrugoksu / iStockphoto.com
11 September 2018Big PharmaGabriel Cuonzo and Luca Pellicciari

Boehringer v Teva: Italian court clarifies boundaries of Bolar privilege

With a ground-breaking decision issued on July 24, 2018, the Milan Court found Teva and its affiliate company Sicor liable for patent infringement in a case concerning Boehringer Ingelheim’s exclusive rights on the active pharmaceutical ingredient (API) tiotropium bromide, used in Boehringer Ingelheim’s product Spiriva for the management of chronic obstructive pulmonary disease.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Novo Nordisk and OpenAI strike AI deal to boost drug discovery
15 April 2026   The Danish pharma giant is turning to artificial intelligence as it faces patent expiry, falling shares and intensifying competition from Eli Lilly.
Big Pharma
Part II: The race to replace semaglutide heats up
23 March 2026   With Novo Nordisk's core semaglutide patent expired in India last week, the company that built one of the most successful drugs in pharmaceutical history is already fighting on a new front. So what comes next?
Big Pharma
Sandoz strikes fresh biosimilar deal with South Korean biotech
19 March 2026   The Swiss generics giant secures global commercialisation rights as partnership targets multi-billion-dollar loss-of-exclusivity opportunity.


Editor's picks

From the courtroom: Hikma v Amarin SCOTUS oral arguments
Americas
From the courtroom: Hikma v Amarin SCOTUS oral arguments
30 April 2026

Editor's picks

Americas
From the courtroom: Hikma v Amarin SCOTUS oral arguments
30 April 2026
Biotechnology
Closing the women's health gap offers ‘benefits for all’
7 April 2026
Europe
European patent offices raise fees
2 April 2026
Americas
Argentina’s patent reset: Why pharma can no longer ignore Latin America's second-largest market
1 April 2026
Europe
WIPR debuts Global In-House Elite 2026
26 March 2026
Biotechnology
mRNA litigation: Who’s winning, who’s filing, and what’s next
25 March 2026

More features

US judge allows rare patent defence in ‘world’s smallest heart pump’ suit
WATCH: John Ward, trademarks VP and associate GC of Moderna, at INTA
Brussels under scrutiny for IP policy as US flags risks to innovation
Squire Patton Boggs promotes partner to head Europe IP&T practice
From the courtroom: Hikma v Amarin SCOTUS oral arguments
Moderna loses key mRNA patent in European vaccine fight
CureVac targets Moderna with 10-patent suit over Spikevax
Safeguarding critical IP in a high-risk era: WIPR Trade Secrets West 2026